


# Fact Sheet

By: Team Crunch  
Time



## Biotech Firm Specialized in **Non-Invasive** Cancer Screenings

### Objectives

- Expand hospital & insurance partnerships.
- Invest in AI diagnostics & multi-cancer screening.
- Achieve 5x revenue growth & profitability by 2025.

### Target Audience

- Private equity firms seeking high-growth healthcare investments.
- Investors in biotech, diagnostics, or healthcare.
- Firms looking for pre-IPO opportunities.

### Key Performance Indicator (KPI)

- Revenue growth: \$680M (2024) → \$1.95B (2029).
- Gross margins: 69% (2024) → 75% (2029).
- New hospital & insurance partnerships.
- Profitability by 2025, net income \$424M (2029).
- R&D expansion & FDA approvals.

### Conclusion

OncoGuard is scaling fast with AI-driven cancer diagnostics. Strong financials, strategic partnerships, and a clear exit strategy make it a top investment opportunity. With growing market demand and cutting-edge technology, it is well-positioned for long-term success in precision oncology.